Application note: Attaining high transient titers in CHO cells
The ability to produce transient CHO derived proteins early during biotherapeutic development is highly desirable to mimic, as closely as possible, the final critical quality attributes of the protein when manufactured at bioproduction scales. Unfortunately, CHO cells typically express lower levels of protein than HEK293 in transient systems, in some instances 50–100 times less than the best 293-based systems, and only modest titer improvements are obtained through the optimisation of individual components of existing transient CHO workflows.
To address the significant unmet need for higher transient CHO protein titers, we employed systems-based approaches whereby the latest advances in cell culture media, feeds, transfection reagents, and expression enhancers were optimised in conjunction with a new high-expressing CHO cell clone.
The goal was to generate a simple and robust workflow for transient protein expression in CHO cells capable of generating gram-perlitre protein titers in 10–14 days, titers previously attainable only by stably expressing cells in a bioreactor setting. These advances allow for unprecedented access to CHO-derived proteins during therapeutic candidate selection and may serve to revolutionise the use of CHO cells for transient protein expression during the early stages of drug development…
This application note is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Enhancing the scientific experience using laboratory software
- Biopharmaceutical bioseparation systems market to value $20bn
- The importance of sterility testing in biopharmaceutical manufacturing
- HPLC market to grow by $1.26bn in five years
- Coupling large molecules with targeting and delivery mechanisms to augment intracellular delivery